Page 1

British Columbia , Canada ( State or other jurisdiction of incorporation ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION 222 Third Street , Suite 2241 Cambridge , Massachusetts Washington , D.C. 20549 FORM 8 - K CURRENT REPORT Pursuant to Section 13 or 15 ( d ) of the Securities Exchange Act of 1934 Date of report ( Date of earliest event reported ) : May 10 , 2021 ( Address of principal executive offices ) VBI VACCINES INC . ( Exact name of registrant as specified in its charter ) 001-37769 ( Commission File Number ) 02142 ( Zip Code ) ( 617 ) 830-3031 N / A ( IRS Employer Identification No. ) ( Registrant's telephone number , including area code ) N / A ( Former Name or former address , if changed since last report ) Check the appropriate box below if the Form 8 - K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions : ☐ Written communications pursuant to Rule 425 under the Securities Act ( 17 CFR 230.425 ) ☐ Soliciting material pursuant to Rule 14a - 12 under the Exchange Act ( 17 CFR 240.14a - 12 ) Pre - commencement communications pursuant to Rule 14d - 2 ( b ) under the Exchange Act ( 17 CFR 240.14d - 2 ( b ) ) ☐ Pre - commencement communications pursuant to Rule 13e - 4 ( c ) under the Exchange Act ( 17 CFR 240.13e - 4 ( c ) ) Securities registered pursuant to Section 12 ( b ) of the Act : Title of each class Common Shares , no par value per share Trading Symbol ( s ) VBIV Name of exchange on which registered The NASDAQ Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 ( $ 230.405 of this chapter ) or Rule 12b - 2 of the Securities Exchange Act of 1934 ( §240.12b - 2 of this chapter ) . Emerging growth company X If an emerging growth company , indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13 ( a ) of the Exchange Act . X Item 2.02 Results of Operations and Financial Condition . On May 10 , 2021 , VBI Vaccines Inc. issued a press release announcing its financial results for the first fiscal quarter ending March 31 , 2021 and provided a corporate update . A copy of this press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference . In accordance with General Instruction B.2 of Form 8 - K , the information in this Current Report on Form 8 - K , including Exhibit 99.1 , that is furnished pursuant to this Item 2.02 shall not be deemed to be " filed " for the purposes of Section 18 of the Securities Exchange Act of 1934 , as amended ( the " Exchange Act " ) , or otherwise subject to the liabilities of that section , and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933 , as amended , or the Exchange Act , except as shall be expressly set forth by specific reference in such filing . Item 9.01 Financial Statements and Exhibits . ( d ) Exhibits Exhibit No. Description Press Release dated May 10 , 2021 * 99.1 * This exhibit is furnished pursuant to Item 2.02 and shall not be deemed to be " filed . "